Shares of Recce Pharmaceuticals (ASX:RCE) climbed as much as 24.6% to an impressive A$0.76, reaching their highest point since the 19th of June.

The pharmaceutical company has announced that its RECCE 327 Gel (R327G) has shown significant promise in treating multiple antibiotic-resistant infections under the Therapeutic Goods Administration’s Special Access Scheme Category A.

This makes it an asset in dealing with health crises that conventional medicine struggles to control.

Furthermore, the company stated that the gel has achieved a >99.99% reduction against Methicillin-resistant Staphylococcus aureus.

This serious hospital-acquired infection frequently results in high morbidity and mortality rates, and this was observed in an ex-vivo burn wound study.

The company is currently in the process of preparing for clinical trials across various unmet medical needs.

However, despite the recent climb, the company’s stock is down 7.6% year-to-date, as of its last close.

Recce Pharmaceuticals (ASX:RCE) is a company that specialises in the development of antibiotics specifically intended to defeat resistant strains of bacteria.